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ABSTRACT  
 
Vitamin D is unique among the vitamins in that humans can synthesize it via the 
action of UV radiation upon the skin. This combined with its ability to act on specific 
target tissues via Vitamin D Receptor’s (VDR) make its classification as a steroid 
hormone more appropriate. While Vitamin D deficiency is a recognized problem in 
some northern latitude countries, recent studies have shown even in sunny countries 
such as Australia, vitamin D deficiency may be more prevalent than first thought. 
Vitamin D is most well known for its role in bone health, however, the discovery of 
VDR’s on a wide variety of tissue types has also opened up roles for vitamin D far 
beyond traditional bone health. These include possible associations with autoimmune 
diseases such as multiple sclerosis and inflammatory bowel diseases, cancer, 
cardiovascular diseases and muscle strength.  Firstly, this paper presents an overview 
of the two sources of vitamin D: exposure to ultraviolet-B radiation and food sources 
of vitamin D, with particular focus on both Australian and international studies on 
dietary vitamin D intake and national fortification strategies. Secondly, the paper 
reviews recent epidemiological and experimental evidence linking vitamin D and its 
role in health and disease for the major conditions linked to suboptimal vitamin D, 
while identifying significant gaps in the research and possible future directions for 
research.   
 
                     vitamin D, ultraviolet, bone health, cancer prevention 
 
 
 
 
 
 2
INTRODUCTION 
 
 
Most of our vitamin D is produced via exposure of the skin to UV radiation through 
sunlight exposure, with relatively small amounts also provided by dietary sources. 
Due to our reliance on the sun for most of our vitamin D, it has been known as the 
‘Sunshine Vitamin’ in the past, which is an especially relevant name for vitamin D in 
a sunny country such as Australia, where it has been estimated that we receive 90-
95% of vitamin D from the sun’s UV radiation1. This creates a dilemma whereby our 
main source of this essential vitamin is via a known carcinogen that has been shown 
to increase risk of skin cancers and be associated with other detrimental effects such 
as eye damage2. Foods contribute only relatively small amounts of vitamin D, 
however useful amounts of vitamin D are found in foods such as fortified margarine 
(these are mandatorily fortified in Australia), fortified milks, eggs, and fish species 
like North Sea salmon, herring and mackerel3. 
 
Due to Australia being considered a sunny country, vitamin D deficiency (defined as 
serum 25(OH)D <50nmol/L) and insufficiency (50-75nmol/L), until recently, was 
only thought to be a major health problem in certain population groups such as the 
institutionalized elderly. Recent studies, however, have shown that vitamin D 
insufficiency is more widespread then first thought4,5. While severe vitamin D 
deficiency causes rickets in children and osteomalacia in adults, vitamin D deficiency 
is also associated with an increased risk of osteoporosis and falls, as well as emerging 
evidence that vitamin D may play a role in reducing the risk of certain cancers, 
autoimmune diseases and hypertension4.  
 
In the first part of this review paper we present an overview of the two sources of 
vitamin D: ultraviolet radiation and diet and investigate the controversies surrounding 
both of these sources. The second part of this paper provides a review of the evidence 
in regard to vitamin D’s role in human health, with a particular focus on its role in 
bone health, muscle strength and cancer. While this paper has an Australian emphasis, 
the implications of vitamin D deficiency and ongoing dilemma of our main source, 
ultraviolet-B radiation, also being a human carcinogen, ensure an international 
relevance.    
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VITAMIN D NOMENCLATURE 
 
As vitamin D exists in a number of forms and these terms are used throughout this 
review, an introduction to these major forms of vitamin D is necessary. Table 1, 
below, provides an overview of the four main forms of vitamin D discussed in this 
review. Ergocalciferol (vitamin D2) is produced by ultraviolet irradiation of ergosterol 
in plants and cholecalciferol (vitamin D3) is produced by ultraviolet irradiation of 7-
Dehydrocholesterol in the skin of vertebrates6. Both 25-hydroxyvitamin D and 1,25 
dihydroxyvitamin D are produced by subsequent hydroxylation of cholecalciferol in 
the human body and are the main circulatory and physiologically active forms in the 
human body, respectively. It is worth noting that activated forms of vitamin D such as 
1,25 dihydroxyvitamin D are rarely used in clinical due to higher risk of 
hypercalcemia7. 
 
 
Table 1: Vitamin D nomenclature 
Name Comments 
cholecalciferol Synthesised in skin by UVB irradiation  
Naturally occurs in some oily fish 
Used as fortificant in some foods and supplements 
More bioavailable then ergocalciferol 
 
ergocalciferol Synthesised by UVB irradiation of plant steroid 
ergosterol.  
Naturally occurs in some mushrooms 
Allowable as a fortificant in some foods and 
supplements (rarely used, however) 
Potentially lower bioavailability then cholecalciferol 
 
 
25-hydroxyvitamin D Produced by hydroxylation of cholecalciferol in the 
liver 
Main serum biomarker of vitamin D status as reflects 
both dietary intake and UV exposure derived 
production. 
 
1, 25 dihydroxyvitamin D Hormonal form produced by hydroxylation of 25-
hydroxyvitamin D. 
 
(modified from Johnson and Kimlin7) 
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ULTRAVIOLET RADIATION 
 
Solar radiation consists of a continuous spectrum of radio, microwaves, X-rays, 
visible, infrared and ultraviolet radiation8. Of these, the ultraviolet (UV) spectrum 
receives the most attention due to both its positive and negative effects on human 
health8. A range of UV wavebands exist, although only the ultraviolet-A (UVA, 320-
400nm) and ultraviolet-B (UVB, 290-320nm) wavebands reach the earth’s surface, 
with the extreme, far and ultraviolet-C (UVC) wavebands being filtered out by 
oxygen and ozone before reaching the earth’s surface2. The main beneficial effect of 
UV exposure is the photoproduction of vitamin D synthesis, while negative effects of 
UV exposure include melanoma and non-melanoma skin cancers and eye damage.  
 
Ultra-Violet Radiation and Health 
 
Ultraviolet Radiation and Skin Cancer  
 
Ultraviolet radiation exposure is associated with a number of negative health effects, 
the most important and certainly most researched being the various forms of UV-
induced skin cancers. The typical skin cancers associated with exposure to UV 
radiation are: basal cell carcinomas (BCC), squamous cell carcinomas (SCC) and 
malignant melanomas9. Of these, BCC’s are the most common, making up 
approximately 70-85% of all skin cancers, while SCC’s account for ~15-20% and 
malignant melanomas ~5% of skin cancers in Australia10. Malignant melanoma, is the 
most dangerous form of these skin cancers and is responsible for the majority of 
deaths from skin cancers11. UV exposure appears to the be the main risk factor for 
both BCC and SCC, while other important risk factors as well as UV, such as genetics 
and number of naevi exist for malignant melanoma2.  
 
 
Skin cancer is of particular concern in Australia, due to high annual sunshine and the 
major role outdoor activity plays in many people’s lifestyles generally. Thus, it comes 
as no surprise that Australia has the highest rate of skin cancer in the world, with one 
in two Australians being diagnosed with skin cancer in their lifetime and over 1600 
deaths being attributable to skin cancer each year in Australia12. Sun protection 
messages and promotional campaigns such as Slip Slop Slap and Sunsmart have 
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attempted to reduce this high rate of skin cancer, by promoting sun safe messages 
such as avoidance of the sun between 10am-3pm and the use of a Sun Protection 
Factor 30+ sunscreen13. Recent evidence seems to show they may be having the 
desired effect, with reported reductions in rates of non-melanoma skin cancer reported 
in people under 50 year olds, at least partly attributable to these campaigns14.  
 
Mechanisms of UV Carcinogenesis and Mutagenesis 
 
Both UVA and particularly UVB radiation exposure appear to contribute to the risk of 
developing skin cancers through different mechanisms14. UVB radiation, whose 
photons are absorbed by DNA, has been shown to exert carcinogenic effects via 
production of photoproducts from DNA bases such as cyclobutane pyrimidine 
dimmers (CPD’s) and pyrimidine-pyrimidone (6-4) photoproducts (6-4PP’s), which 
exert carcinogenic effects on the epidermis8. Additional carcinogenic effects of UVB 
include suppression of immune function and upregulation of gene expression which 
may enhance tumor development15. UVA radiation appears to induce carcinogenic 
effects indirectly via Reactive Oxygen Species (ROS), which cause DNA breaks and 
oxidation of nucleic acid bases16. An area of particular interest is the recent research 
into the UV-induced mutation (at bipyrimidine sites) of the p53 tumor suppressor 
gene, which is responsible for regulating DNA repair and apoptosis17. Mutations in 
this gene, inhibit its ability to carry out DNA repair or apoptosis of damaged cells, 
increasing risk of tumor development16.  
 
Epidemiological evidence for role of UV in Skin Cancers 
 
Epidemiological evidence suggests a strong relationship between UVR exposure and 
non-melanoma skin cancers (NMSC)18. The epidemiological evidence for UVR and 
malignant melanoma is rather more complex, as other factors such as genetics also 
play a role in melanoma development2. There is strong evidence linking average 
annual UVB exposure to melanoma risk, however melanoma risk association using 
latitude gradient studies have provided much more inconsistent evidence18.While it is 
acknowledged that UV exposure plays the greatest role in determining melanoma risk 
in European populations, gaps in the research do exist in regard to the role of UVR in 
the etiology of malignant melanoma 8,19. Animal and in-vitro models have contributed 
much to our understanding of the carcinogenic effects of UV radiation. However, 
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with UV radiation impacting on many biological processes linked to carcinogenesis 
and mutagenesis in humans, the full picture is far from complete and further major 
discoveries to advance our knowledge in this field are certain.  
 
Other health effects of ultraviolet radiation 
 
Although the main focus of this section has been the relationship between ultraviolet 
radiation and skin cancer, UV radiation also impacts on other areas of health. 
Ultraviolet radiation exposure is thought to be a major cause of eye damage, although 
the epidemiological evidence is only sufficient to confirm a causal association with 
photokeratitis (snow blindness), with more limited evidence for pterygium, cataracts, 
climatic droplet keratopathy and anterior lens capsule changes20. Other negative 
effects of UV radiation include photoaging and sunburn2.   
 
Ultraviolet Radiation and Vitamin D 
 
While there are a number of deleterious effects of UV radiation exposure on the 
human body of which skin cancers are the most severe, there are also benefits in the 
form of vitamin D synthesis. UVB radiation (in the 280-320nm spectrum) is the main 
source of vitamin D for humans21. The UV catalyses a reaction in the human 
epidermis whereby 7-dehydrocholesterol (7-DHC) is converted to cholecalciferol 
(vitamin D3), in a two step process, which then undergoes two hydroxylations in the 
liver and kidney to produce the active form of the vitamin: 1,25 
dihydroxycholecalciferol (1,25(OH)2D)22. In this way an estimated 90-95% of our 
Vitamin D (at least in Australia) is formed, with dietary sources making up the 
balance23. Figure-1, provides a simplified version of Vitamin D production in the 
human body.  
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   Fig. 1. Vitamin D sources and activation 
                                          
                                                   Nowson and Margerison22 
 
Vitamin D production in human skin is determined by a number of factors such as 
time of day, latitude, season, skin colour, and age. People with more darkly 
pigmented skin are at higher risk of vitamin D deficiency due to melanin competing 
with 7-DHC for UV absorption24. Vitamin D production is also less efficient in the 
elderly due to age-associated decreases in skin 7-DHC25. Latitude, season and time of 
day also influence vitamin D synthesis via the Solar Zenith Angle (SZA), which 
effects the amount and distribution of solar radiation reaching the earth’s surface ie. 
small SZA’s are associated with summer, noon and latitudes closer to the equator thus 
increasing skin exposure to UVB radiation and vitamin D synthesis26. However, 
recent research has shown that erythemal UV latitude gradients may not be as 
important as once thought for vitamin D synthesis and other factors such as total 
ozone, cloud cover, aerosols, surface reflectivity and altitude that also effect vitamin 
D production in the skin, may play a greater role27. 
 
Required levels of sun exposure for adequate Vitamin D synthesis 
 
There is a major concern that with public health messages focusing on reducing sun 
exposure, people are not producing enough vitamin D. Indeed, even in sunny 
Queensland, Australia, which is the known as the ‘skin cancer capital of the world’, a 
recent study showed 42.5% of participants were Vitamin D deficient in winter28. This 
creates a dilemma, whereby people avoiding UV exposure to significantly reduce 
their risk of skin cancers and other harmful UV effects may actually also be 
 8
increasing their risk of vitamin D insufficiency and even deficiency. Therefore it is of 
great interest for researchers to find out how much UV exposure is needed to produce 
adequate vitamin D and whether there is a safe level of UV exposure. Samanek et al.29 
attempted to shed light on this issue with an ecological study design using Ultraviolet 
Index data collected from major Australian population centres in a one year study. 
This study used a model based on Fitzpatrick type-II skin types (white skin that 
always burns easily), with a 15% skin exposure and between 1/6 to 1/3 of a Minimal 
Erythemal Dose (which is the time taken for UV radiation to cause a slight reddening 
of the skin), this MED figure was the calculated UV dose needed to produce adequate 
vitamin D29. For example, in January, in Brisbane, Australia, between 2-4 minutes of 
sun exposure a day was needed during summer months, at noon, to produce enough 
vitamin D, based on daily vitamin D requirements29.  
 
Obviously, seasonal changes and time of exposure changed the amount of sun 
exposure needed and increased exposure times were needed in population centres 
with lower latitudes. There were numerous weaknesses in the study eg. It did not take 
into account factors such as aging that effect vitamin D synthesis, was conducted over 
a relatively short length of time and only provided recommendations for one skin 
type. Despite these weaknesses, it provides important information on doses of sun 
exposure needed for adequate vitamin D synthesis while avoiding dangerous over 
exposure to the sun. Other studies26,30 have also provided data on estimated UV 
exposure times required for vitamin D synthesis using in-vitro systems such as 
spectrophotometric analysis of the previtamin-D content in ethanol solutions of 7-
DHC during UV exposure. A particular strength of the study by Webb & Engelsen26 
was that it predicted sun exposure times needed for adequate vitamin D synthesis for 
different skin types. 
 
It may be some time before we are able to accurately predict ‘safe’ levels of sun 
exposure that result in adequate vitamin D synthesis, but do not result in increased 
risk of skin cancers if, indeed, such an ideal exists. While research, does, so far, show 
us how complex UV exposure and vitamin D research really is, the Cancer Council of 
Australia has released broad recommendations on how to achieve adequate vitamin D 
production while remaining ‘sunsmart’31. For instance recommendations made by the 
Cancer Council of New South Wales state that exposing face, hands and arms for 10 
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minutes in summer, 15-20 minutes in spring and autumn and 30 minutes in winter 
outside the peak UV times (10am-3pm) should be adequate to produce enough 
vitamin D32.  
 
 
 
 
VITAMIN D AND DIET 
 
Vitamin D Food Sources 
 
Dietary intake contributes only small amounts of vitamin D overall, with vitamin D 
found in reasonable amounts in North Sea oily fish such as salmon, herring, sardines 
and tuna (4-25ug/100g), egg (1.8ug/100g), butter (1.4ug/100g) and red meat and liver 
(0.7-1.1ug/100g)3. The vitamin D within the same food products may also vary, with 
recent research showing that the vitamin D content of fish may vary enormously 
depending on whether fish is farmed or wild. For instance, Chen et al.33 analyzed the 
vitamin D content of both wild and farmed salmon and discovered that wild salmon 
contained four times the vitamin D content of farmed salmon. Despite the relatively 
low amount of dietary vitamin D found naturally in foods, there is a growing interest 
in the role of vitamin D fortified foods and supplements in improving vitamin D 
status.  
 
 
Vitamin D dietary Intake in Australia 
 
In regard to the actual amount of vitamin D we receive from food, it is apparent that 
vitamin D intake in Australia is low, with study data showing that Australians on 
average only consume 2-3ug/day of vitamin D a day from dietary sources34. This 
shows that on average, Australians are well below meeting the 5, 10, 15ug/day of 
dietary vitamin D recommended for <50, 50-70 and 70+ age groups respectively35. 
Another interesting finding from this study was that, on average, 50% of the 
Australian population’s vitamin D intake is sourced from fortified margarine 
products34. This study formed part of the CSIRO (Commonwealth Scientific and 
Industrial Research Organisation) National Diet Survey and used a semi-quantified 
Food Frequency Questionnaire (FFQ) sent out in two batches of 5,000 postal surveys, 
to randomly selected households from the electoral roll in 1998 and 199934. 
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Limitations included the lack of any data collected on vitamin D supplements and the 
relatively low participation rate of 43%. However, this study is to date, the only 
comprehensive nationwide survey that has collected information on dietary vitamin D 
intake in this country, so the data collected is of great significance. 
 
Only a few other studies have attempted to collect information on dietary vitamin D 
intake in Australians. Jones et al.36 and Sherwin et al.37 collected data on the vitamin 
D intake of 201 children with a FFQ and 215 females in residential care or nursing 
homes using a plate waste survey, respectively22. These two studies reported dietary 
vitamin D intakes that were approximately half of those recorded in the CSIRO 
National Diet Survey  (1ug/day and 0.9ug/day (median) respectively), which is to be 
expected due to the lower food intakes associated with children and 
residential/nursing home residents. Another contributor to the lower reported intake in 
the study by Jones et al.36 would almost certainly be the lack of data collected on 
margarine, which, as mentioned previously, is a major contributor to dietary vitamin 
D intake in this country34. Pascoe et al.5 also collected data on the vitamin D intake of 
women ranging in age from 20-92 in a much larger study (n=861, randomly selected), 
as part of the Geelong osteoporosis study and found median intakes of 1.2 ug/day, 
using an FFQ. This study also reported 7.9% of participants used vitamin D 
supplements, which resulted in an increase to the median vitamin D intake of 0.1 
ug/day (for a total of 1.3ug/day)5.   The findings from this study showed a significant 
association between dietary vitamin D intake and vitamin D status in winter, but no 
significant association between these two variables in summer. It also highlighted the 
limited use of vitamin D supplements in this group, although further studies into 
vitamin D supplement use are needed to confirm whether this is common to other 
parts of Australia or has changed over the past 7 years5.  
 
International Vitamin D dietary intake  
 
International studies into dietary vitamin D status have shown quite varied results, 
reflecting national trends in food consumption and the use of food fortification38-44. 
However, comparison between different countries is very difficult, due to the wide 
variety of different FFQ’s food recall times used, which can range from 3 days to 1 
year. Also, some studies, such as the large Multi Ethnic Cohort study (n=191,011) 
measured supplement intake of Vitamin D in participants, while others such as the 
 11
UK European Prospective Investigation into Cancer and Nutrition (n=65,469) did 
not38,40. Additionally, many studies also reported means (which may reflect extreme 
values) rather than medians. Table-2 shows the reported vitamin D intakes from 
various international studies.  
 
The data presented in Table-2 shows intakes averaging 1-3 ug /day in studies from the 
UK, Tunisia, Turkey and Switzerland, which is similar to the Australian intakes 
reported above40-42,44. However, dietary intake of vitamin D appears higher in the two 
studies investigating reported intake of vitamin D in the United States and the study 
from Finland38,39,43. This may be partially explained by the fact that these three studies 
reported supplemental intake of vitamin D while the other studies presented in Table-
2 did not. Also, the more widespread food fortification practices used in both the US 
and Finland are primary predictors of dietary vitamin D intake in these countries, with 
intakes 60% higher in these countries than in New Zealand, where vitamin D 
fortification of the food supply is at a similar level to Australia’s 11. 
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Table 2: International Dietary Vitamin D intakes   
 
Author Country Data Collection 
Method/ 
Supplement use 
reported yes/no 
Study/ 
Participants/ 
Age/Gender 
Vitamin D intake/ 
Day* 
Park et al.38 USA FFQ 
Supplements: 
Yes 
Cohort  
(n=191,011) 
Age=45-75 
Males and 
Females 
Males=8.38ug 
Females=8.50ug 
Wang et al.39 USA FFQ 
Supplements: 
Yes 
Cohort 
(n=28,886) 
Age= >45 
Females 
 
Quintiles 
(median) 
1st= 2.75ug 
2nd= 4.17ug 
3rd= 5.40ug 
4th= 6.88ug 
5th= 9.53ug 
Roddam et al.40 UK FFQ 
Supplements: 
No 
Case-Control 
(n=2,175) 
(Cases=incident 
fractures) 
Age=>20 
Males and 
Females 
Males,    
cases=2.82ug     
controls=2.95ug 
 
Females, 
cases=3.06ug          
controls=2.97ug 
 
Meddeb et al.41 Tunisia FFQ 
Supplements: 
No 
Cross-Sectional 
(n=389) 
Age=20-60 
Male and Female 
Males=2.05ug 
Females=1.29ug 
Gannage-Yared, 
Chemali, Yaacoub et 
al.42  
Turkey FFQ 
Supplements: 
No 
Cross-Sectional, 
(n=316) 
Age=30-50  
Males and 
Females 
Males=3.2ug 
Females=2.2ug 
Lamberg-Allardt et 
al.43 
Finland FFQ 
Supplements: Yes 
Cross-Sectional 
(n=328) 
Age=31-43 
Males and 
Females 
Males=5.6ug 
Females=4.7ug 
Morabia et al.44 Switzerland FFQ 
Supplements: 
No 
Cross-Sectional 
(n=2,319) 
Age=35-74 
Females 
Heavy 
Smokers=1.92ug 
Moderate 
Smokers=2.28ug 
Never 
Smokers=2.39ug 
                    *All values means unless 
                        otherwise stated. 
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Vitamin D food fortification  
 
Fortification practices in different countries are varied, for example, in Australia we 
mandatorily fortify margarine and food manufacturers can voluntarily fortify some foods such 
as modified milks and skim milks, with ergocalciferol, which in practice is not used, or 
cholecalciferol but few of these vitamin D fortified products are available22,45. Foods allowed 
for fortification and the quantity of cholecalciferol/ergocalciferol allowed, as outlined by the 
Australian and New Zealand Food Standards Code, is presented in below in Table-3. 
 
Table-3: Maximum quantity of ergocalciferol/cholecalciferol fortification allowable in 
permitted Australian and New Zealand foods 
  
Food  Maximum quantity of  permitted Vitamin D 
(cholecalciferol or ergocalcalciferol) per serve 
of food 
Dairy 
Dried milks 
Modified milks and skim milks 
Cheese and cheese products 
Yoghurts with or without other foods 
Dairy desserts*  
Butter 
 
 
3ug/200ml 
1.6ug/200ml 
1.6ug/25g 
1.6ug/150g 
1.6ug/150g 
1.6ug/10g 
Edible oils and spreads 
Edible oil spreads and margarine 
 
 
1.6ug/10g 
Analogues derived from legumes 
Beverages† 
Analogues of yoghurt and dairy desserts† 
Analogues of cheese‡ 
 
 
1.6ug/200ml 
1.6ug/150g 
1.6ug/25g 
Analogues derived from cereals 
Beverages§ 
 
 
1.6ug/200ml 
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Formulated beverages 
 
2.5ug/600ml 
* containing no less than 3.1% m/m of protein derived from milk protein 
† containing no less than 3.1% m/m of protein derived from legume protein 
‡ containing no less than 15% m/m protein derived from legumes 
§ containing no less than 0.3% m/m protein derived from cereals 
Source: Food Standards Australia New Zealand45 
 
The UK mandatorily fortify margarine with a fat content of 80% or above, while in the US, 
only milks labeled as 'fortified' have to actually be fortified with vitamin D, however more 
products are able to be fortified in both the US and the UK, such as breakfast cereals22. 
Indeed, breakfast cereals in the UK have been shown to provide 13% of the mean intake of 
Vitamin D for adults, thus contributing a major source of Vitamin D in the UK46. Both 
Canada and Finland have introduced mandatory fortification on milk and margarine and in 
Finland at least, this seems to have had a positive impact on vitamin D status, at least during 
winter47. For instance, a study on a group of young Finnish males showed that 78% had 
vitamin D levels below 40nmol/L, but after 1 year of fortification being introduced, only 35% 
of them had vitamin D levels under 40nmol/L, furthermore there was a mean 50% increase in 
vitamin D levels47. This study shows the significant effect food fortification can have on 
improving vitamin D status in a country where sun exposure is limited, especially during 
winter. More widespread fortification may also have a more important role in maintaining 
adequate vitamin D status in the future for sunny countries such as Australia
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VITAMIN D AND DETERMINANTS OF HEALTH 
 
Vitamin D Receptors (VDR) are present on many tissues and organs in the body and 
as such vitamin D has been identified as playing a role, or a potential role, in many 
human diseases and conditions. Vitamin D’s role in bone health is well known, with 
osteomalacia and rickets the traditional conditions associated with serious vitamin D 
deficiency. Vitamin D’s role in reducing the risk of osteoporosis is also seen as a 
major function of the vitamin. Emerging research has also highlighted possible roles 
for vitamin D in reducing the risk of certain autoimmune diseases (eg type-1 
diabetes), some cancers (such as colon cancer), cardiovascular disease and the 
maintenance of muscle strength in older adults48. 
 
With vitamin D’s wide range of target tissues and actions, it is not surprising that its 
involvement in the disease processes of multiple health conditions has been widely 
researched. The following sections review the major research conducted in regard to 
Vitamin D’s role in health and disease. 
 
Optimal vitamin D levels for health 
 
What constitutes a ‘normal’ or ‘optimal’ serum 25(OH)D level for health has been an 
area of some debate. Although several measures of deficiency and insufficiency exist, 
commonly used criteria for defining levels of vitamin D deficiency, based on the 
measurement of serum 25-hydroxyvitamin D, are provided below: 
 
 <12.5nmol/L: severe 
 12.5-25nmol/L: moderate deficiency 
 25-50nmol/L: mild deficiency 
 >50nmol/L-75nmol/L: insufficiency 
 >75nmol/L sufficiency 
 
Lips49, ANZBMS Position statement50, Holick 51 
 
It is important to note here that serum 25(OH)D status is generally used to define 
vitamin D status rather than serum 1,25(OH)2D. This may seem counterintuitive, 
however serum 1,25(OH)2D is thought to be a poor indicator of vitamin D status as it 
is able to be produced locally by many tissues and is not depressed when people 
display mild to moderate serum 25(OH)D deficiency with raised PTH7. 
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These commonly used criteria are based on the physiological effects that low serum 
25(OH)D status induces on bone, calcium absorption and serum PTH. Levels of 50-
75nmol/L, now cited by many authors as vitamin D insufficiency, are associated with 
decreased calcium absorption and a small increases in PTH release (Note that PTH 
only stabilises at approximately 100nmol/L)51 Mild deficiency, also confusingly 
termed insufficiency by some authors in the past, is associated with higher bone 
turnover and increases in PTH release, moderate deficiency is associated with 
increased bone turnover and moderate increases in serum PTH levels, while severe 
deficiency is associated with high bone turnover leading to osteomalacia and large 
increases in serum PTH levels49. There is, however, still some confusion on cutoff 
levels for determining serum 25(OH)D based on the lack of standardized 
physiological cutoff points to define deficiency and insufficiency and also the use of  
different cutoff points by authors for statistical analysis of deficiency and 
insufficiency in varied population groups.  
 
Definitions to define serum 25(OH)D deficiency and insufficiency have changed over 
time7. Originally the serum 25-hydroxyvitamin D levels of asymptomatic subjects 
was plotted using Gaussian (normal) distributions and this data was used to define 
‘normal’ vitamin D status, but this data is approaching 40 years old and new 
biomarkers to predict at what level 25(OH)D is sufficient, such as PTH and calcium 
absorption, are now available52. A recent paper by six experts in vitamin D research 
has attempted to reduce this confusion by determining, in the expert opinion of the 
authors, the optimal minimal serum 25(OH)D level for fracture prevention53. The 
criteria for determining this level included the level of 25(OH)D required for 
suppression of PTH, optimal Bone Mineral Density (BMD), reduced bone loss, 
fracture and fall risk. After an extensive review of the literature 5 out of the 6 authors 
agreed that 70-80nmol/L was a minimal optimal 25(OH)D level for bone health, with 
1 author estimating 50nmol/L due to the lack of evidence at this time for the broad 
population supplementation needed to reach the higher levels53. This is a valid point, 
as food intake alone is extremely unlikely to raise concentrations of 25(OH)D to the 
optimal levels mentioned above in the general population, without widespread 
supplementation or sun exposure53.  
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Some trials with vitamin D supplementation have shown that higher doses of vitamin 
D, 800IU daily or 100,000IU four-monthly, are needed to raise serum 25(OH)D levels 
to a mean of approximately 75nmol/L and it is these higher levels of supplementation 
that have been shown to provide the most significant benefits in fall and fracture 
risk53. Together these findings seem to support a minimal optimal threshold of 70-
80nmol/L for serum 25(OH)D levels, for the reduction of fracture and fall risk. Thus 
the use of >75nmol/L as a definition for sufficient serum 25(OH)D status is used in 
this review paper. A weakness in these guidelines, however, is that they refer to 
optimal serum 25(OH)D levels for bone health and may not apply to other health 
conditions linked to vitamin D such as cancer. Serum 25(OH)D levels of >75nmol/L, 
have however, shown that they may significantly reduce the risk of some types of 
cancers and there is agreement among many experts that levels of serum 25(OH)D 
>75nmol/L may be beneficial for cancer risk reduction54. Recommendations of 
optimal levels of serum 25(OH)D for prevention of other disease unrelated to bone 
health such as cancer may at this stage may be premature, however, due to the relative 
lack of consistent epidemiological data for other health endpoints associated with 
serum 25(OH)D status  
 
 
Vitamin D and osteoporosis 
 
Osteoporosis is a serious condition associated with a gradual loss of bone density, 
resulting in weak, brittle bones. In Australia, it is estimated that 1 in 2 women and 1 
in 3 men will have an osteoporotic fracture and every 8 minutes someone is admitted 
to a hospital with an osteoporotic fracture55. Osteoporosis is a disease associated with 
advancing age due to increasing rates of bone losses, which results in a lower bone 
density56. Females are also at a significantly greater risk due to decreases in estrogen 
during menopause. Estrogen stimulates bone remodeling, thus a reduction in estrogen 
levels results in increased bone losses through increased bone resorption56. Other 
important risk factors for osteoporosis include:  fragility or low impact fracture in a 
first degree relative, low body weight, smoker, use of corticosteroid medication 
>3months, early menopause, low calcium intake, low serum 25(OH)D and decreased 
physical activity (especially weight bearing)57. The main sites of fracture involve the 
wrist, vertebrae and hip and these not only result in significant decreases in mobility 
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and in quality of life for patients, but major fractures are also associated with 
increased mortality following the fracture58.  
 
Vitamin D’s role in bone health 
 
Severe serum 25(OH)D deficiency is associated with the vitamin D deficiency disease 
of osteomalacia, which results in defective mineralization of the osteoid on the 
cortical and trabacelar surfaces of bone59. Osteomalacia results in bone and muscle 
pains and increased risk of fractures, and although it is a condition thought to be rare 
in Australia, limited data exists on it prevalence worldwide50. 
The active form of vitamin D, 1,25(OH)2 D, is also thought to play an important role 
in the pathogenesis of osteoporosis through its role in calcium and bone metabolism, 
via numerous mechanisms. Promotion of active calcium absorption through the 
intestine via the nuclear VDR by 1,25 dihydroxyvitamin D is one of the most widely 
understood mechanisms60. This is especially important when calcium intake is low, 
but less so when calcium intake is high, which results in a higher passive transport of 
calcium into the circulation and decreased active, 1,25(OH)2D mediated, transcellular 
transport61. However, calcium absorption is not the only role that 1,25(OH)2D plays in 
bone health as it also stimulates bone maturation, matrix formation, renal reabsorption 
of calcium, bone remodeling and osteoclast cell activity60. Parathyroid Hormone 
(PTH) is essential in regulating calcium and vitamin D metabolism through it roles in 
1,25(OH)2D activation, maintaining calcium homeostasis and bone resorption58.  
To illustrate the relationship between PTH and serum 25(OH)D, Figure-2 shows the 
correlation between reduced serum 25(OH)D levels and higher levels of PTH. It is 
apparent from this scatterplot that there is a gradual increase in plasma PTH level at 
serum 25(OH)D levels below 100nmol/L, while a much steeper increase in plasma 
PTH can be observed when serum 25(OH)D fall below 40-50nmol/L62 This is 
clinically important as the resulting increase in PTH increases hydroxylation of 
25(OH)D to the active 1,25(OH)2D form63. These higher 1,25(OH)2D levels in turn 
assist in maintaining normocalcemia, via increased calcium absorption62. Bone 
resorption, which results in increased calcium ion release into to bloodstream is also 
stimulated by the increased PTH, causing bone losses and reduced bone density58.  
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Fig. 2. Correlation between serum 25-hydroxyvitamin D and PTH 
   
   Mosekilde62 
 
Many epidemiological studies have been conducted investigating the relationship 
between vitamin D and osteoporosis and a significant number of these have been high 
quality RCT’s. Studies exploring the relationship between vitamin D and osteoporosis 
generally either use fractures or indicators of bone density and turnover such as Bone 
Mineral Density (BMD).  
 
Meta-analyses of Vitamin D’s role in osteoporosis  
 
A meta-analysis conducted by Bischoff-Ferrari et al.64 found significant relationships 
between vitamin D supplementation with vitamin D3 and fracture or bone density 
measures. Birshoff-Ferrari et al.64 pooled studies into those using higher vitamin D3 
doses of 700-800IU (17.5-20ug)/day and those using low dose supplements of 400IU 
(10ug)/day and found the higher dose studies were associated with decreasing hip 
fracture by 26% (3 RCT’s with n=5,572, pooled RR=0.76, 95% CI 0.61-0.88) and 
non-vertebral fractures by 23% (5 RCT’s with n=6,098, pooled RR=0.77, 95% CI 
0.68-0.87). No significant results were reported for RCT’s that used vitamin D3 at 
400IU (10ug)/d. Tang et al.65 conducted an even larger analysis encompassing 17 
randomized trials and a total of 63,897 participants over 50 years of age with both 
fracture and bone mineral density as endpoints. This analysis showed that treatment 
with calcium supplements (with or without vitamin D) was associated with a 
reduction in fracture risk of 12% (RR=0.88, 95% CI 0.83-0.95; p=0.0004)65. While 
vitamin D (forms of vitamin D used not reported) did not appear to have a significant 
role in reducing fracture risk, sub group analysis revealed that the addition of vitamin 
D to calcium supplementation did result in a significant treatment effect in those 
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institutionalized compared to the community (RR=0.76 vs 0.94; p=0.003). Tang et 
al.65 additionally reported that the treatment effect was improved if calcium doses 
were 1200mg or higher and vitamin D doses were 800IU and higher.  The results 
from both of these analyses are extremely informative due to the inclusion of only 
intervention trials, however, only Bischoff-Ferrari et al.64 reported a strong dose-
response effect with regard to vitamin D and fracture risk/BMD. The research 
suggests that calcium plays a major role in explaining changes in fracture risk and 
BMD changes and the actual independent role of vitamin D on bone health still needs 
to be elucidated. Also the meta-analysis by Bischoff-Ferrari et al.64 did not include 
several important RCT’s completed recently such as those by Porthouse et al.66 and 
Grant et al.67.  
 
Another comprehensive meta-analysis undertaken by the Cochrane Collaboration 
found vitamin D in various forms by itself had no statistically significant effect on 
new fracture incidence (RR=1.02 CI, 0.93-1.11), however vitamin D and calcium 
where significantly associated with reduced risk of non-vertebral (RR=0.87, 0.78-
0.97) and hip fracture incidence (RR=0.81, 0.68-0.96)68. Again this study supports the 
use of calcium with vitamin D in fracture prevention; however, as in the meta-
analysis by Tang et al.63, vitamin D alone seems to have no significant effect. 
Differences in results between this analysis and the meta-analysis by Bischoff-Ferrari 
et al.62 may be partially explained by differing inclusion criteria and the wide use of 
subgroup analysis in these studies in order to separately analyze the effects of higher 
doses of vitamin D on fracture risk and bone density. 
 
A recent meta-analysis by Bischoff-Ferrari et al.69 assessing the efficacy of vitamin D 
oral supplementation on nonvertebral fractures reported that pooling trials with a 
higher dose then 400IU/d(10ug) of vitamin D was associated with a 20% reduction in 
nonvertebral fractures for people aged 65 and over. This study was significant also for 
it’s inclusion of 12 double bind RCT’s for nonvertebral fracture and 8 RCT’s for hip 
fracture (total N=83,165) and also the finding that this effect was independent of 
calcium supplementation69. This recent study provides support for Biscoff-Ferrari’s 
earlier meta–analysis in that it provides strong evidence for higher dose vitamin D 
supplementation being needed for fracture prevention (ie. >800-1,000IU/d or 20-
25ug/d) and the independent role of vitamin D in fracture prevention. 
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Intervention studies of Vitamin D’s role in osteoporosis 
 
Several intervention studies have been conducted recently investigating the 
relationship between vitamin D and osteoporosis risk (See Table-4 for intervention 
trials)66,67,70-78. Two recent large, intervention trials have shown inverse associations 
between vitamin D supplementation and fracture risk70,72. A large study by Larsen et 
al. 70 showed that participants supplemented with 10ug (400IU) of cholecalciferol and 
1000mg of calcium over a three year period were observed to have a 16% reduction in 
fracture risk compared to those undertaking a domestic environment improvement 
program. The above study by Larsen et al.70 had a number of limitations, however, as 
only relatively small doses of vitamin D3 were used and it was impossible to separate 
the individual effects of calcium and vitamin D on fracture risk. In order to overcome 
this, Trivedi et al72, used a study design whereby vitamin D3supplements only were 
given to participants in four-monthly megadoses of 2,500ug (100,000 IU) and 
compared these to a placebo group over five years. Results showed that first fracture 
risk was reduced by 22% in the intervention group, while fracture risk for common 
osteoporotic sites (hip, wrist and vertebrae) was reduced by 33%72. Two trials using 
BMD as endpoints, rather than fracture incidence have also shown vitamin D3 and 
calcium supplementation or use of vitamin D3 and calcium fortified food products 
were associated with an increase in BMD73,74 (See Table-4). Both of these studies had 
a number of weaknesses including the use of relatively low levels of supplemental 
and dietary vitamin D (7.5-12.5ug/day) and small subject numbers. However, they do 
provide support for the use of vitamin D3 and calcium for bone loss prevention and 
the use of fortified dairy products by Moschonis and Manios73 was particularly unique 
considering the role of other bone nutrients in dairy products in osteoporosis 
prevention.  
 
Other studies have shown no relationships between vitamin D and fracture risk. Five 
recent RCT’s have shown no relationship between vitamin D and fracture risk (See 
Table-4). For instance, Lyons et al.75 reported that four monthly 100,000IU (2,500ug) 
vitamin D2 supplementation was not significantly effective at reducing fractures 
among a older institutionalized elderly over a 3 year follow up. A possible weakness 
of this study was the use of ergocalciferol (Vitamin D2), which has a reportedly lower 
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potency and a shorter duration of action compared to the cholecalciferol (vitamin D3) 
form, although research has also shown that ergocalciferol may be just as effective as 
cholecalciferol in raising serum 25(OH)D status, so this area remains controversial 
79,80. In the Women’s Health Initiative study, a 12% decrease in hip fracture in 
females supplemented with 1000mg calcium and 10ug of vitamin D3 over 7 years was 
reported, but this was not significant71. The relatively small doses of vitamin D3 used 
in this study were a weakness, with other factors such as lower fracture rate due to 
high personal calcium intake and hormone therapy use also possible contributors to 
the lack of any significant improvement71. Another large RCT by Porthouse et al.66 
also found no evidence that fracture was reduced in women taking 20ug vitamin D3 
and 1,000mg calcium. The results from these trials are surprising as three of the 
RCT’s were conducted in the institutionalized elderly, who have in the past been seen 
as the population to most benefit from vitamin D supplementation. Also, several of 
the trials used relatively large doses of vitamin D, which have been associated with an 
improvement in studies such as those by Trivedi et al.72.  
 
Vitamin D’s role in the secondary prevention of fractures 
 
Secondary prevention of fractures is an area frequently overlooked by researchers, 
however it is a very important area considering that risk of fractures increases 
exponentially following the first osteoporotic fracture56. In the NoNOF (Nottingham 
Neck of Femur) study researchers reported that calcium and vitamin D (either 
Vitamin D2 or D3) interventions for elderly women who had suffered a hip fracture 
increased BMD by up to 4.6% over a one year follow up  (See Table 4)76. This study 
was unique as a result of the multiple interventions used and showed that oral vitamin 
D3 and calcium given daily were more beneficial at increasing BMD then injected 
megadoses of vitamin D2 with or without oral calcium76. A second study by the 
RECORD trial Group67, however, showed no significant differences in incidence in 
low trauma secondary fractures for elderly participants on vitamin D3, calcium and 
vitamin D3 or a placebo followed over 24-62 months (See Table 4). The RECORD 
trial was a larger study and was conducted over a longer period of follow up 
compared to the intervention by Harwood et al.76. While both studies used the same 
dose of oral vitamin D3 (20ug/d), direct comparison was difficult as both reported 
different outcomes (BMD vs fractures). However, the RECORD Trial calls into 
question the clinical significance of small BMD increases on fracture risk ie. Despite 
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small increases in BMD does this correspond to decreased risk of secondary fractures 
in the elderly?  Studies assessing both secondary fracture incidence and BMD 
changes are needed to improve the evidence for vitamin D supplementation in this 
field.  
 
Observational Studies of Vitamin D’s role in osteoporosis 
 
At least two large observational studies have also recently showed a relationship 
between 25(OH)D and fracture risk81,82. In these studies serum 25(OH) D levels under 
30nmol/L and 50nmol/L were significantly associated with increased risk of fractures 
in the Longitudal Aging Study Amsterdam (LASA) (n=1311) (HR=3.1; 95% CI 1.4-
6.9) and Osteoporosis Prospective Risk Assessment (OPRA) (n=986) (HR=2.04 95% 
CI 1.04-4.04) studies, respectively81,82. Caution is needed when interpreting these 
results, as Gerdham et al.82 notes that fracture risk in those participants with 25(OH)D 
under 30nmol/L was likely to be in part due to high frailty in this group. However, 
with vitamin D’s proposed role in muscle strength and fall prevention, it is still likely 
to be involved in the causal pathway.  
 
Conversely, the observational OFELY study (n=669) with a long median follow up of 
11.2 years did not report any significant differences in fracture incidence, bone 
turnover or BMD in healthy home-dwelling women when classified according to 
25(OH)D status (<50nmol/L vs >50nmol/L and <75nmol/L vs >75nmol/L83. A 
possible contributing factor for the differences of findings in these studies could be 
that participants in the OFELY study had mean age of 62 which was much younger 
then the mean ages of the participants in the OPRA and LASA studies. The long 
length of follow up for the OFELY study compared to the OPRA and LASA studies, 
however, provides strong evidence that 25(OH)D levels in healthy younger 
postmenopausal women may not be a strong determinant of fracture risk or bone 
turnover. 
 
Summary of Vitamin D’s role in osteoporosis  
 
Despite some strong evidence to support vitamin D’s role in fracture and bone loss 
prevention, recent, well designed intervention and observational studies have cast 
some doubt on this and thus the evidence remains inconsistent. This is particularly 
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true for studies using vitamin D without calcium in order to tease out the individual 
role of vitamin D in bone health. While all the studies reported decreases in PTH in 
response to vitamin D supplementation, changes in other bone measures are 
inconsistent across studies. An overlooked area that may have potential to explain 
some of the inconsistencies in results seen with the research to date are the prevalence 
of osteomalacia in the samples of participants studied. For example, it has been 
reported that up to one third of postmenopausal women have a secondary cause of 
low bone mineral density, which can include osteomalacia84. Thus participants with 
osteomalacia in studies are likely to benefit from vitamin D supplementation and may 
suffer fewer fractures and increases in BMD caused by improvements to osteomalacia 
rather than a protective effect of vitamin D for osteoporosis. Therefore studies with a 
higher proportion of participants with osteomalacia (which is rarely documented) may 
show increased effectiveness of a vitamin D intervention. Other gaps in our 
knowledge include the lack of men recruited, heavy emphasis on European and North 
American populations and the use of widely varying dosages of vitamin D, despite 
strong evidence supporting the use of at least 20ug (800IU) for beneficial effects69,85 . 
This last point is particularly important, especially given the results of the recent 
meta-analysis conducted by Biscoff-Ferrari et al.69, reporting the importance of higher 
dose vitamin D in antifracture efficacy  Despite these inconsistencies calcium and 
vitamin D, when used together in adequate doses, seem to be associated with 
improved bone health, especially in elderly individuals. 
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Table- 4: Recent intervention studies on Vitamin D on fracture risk or bone losses. 
 
AUTHOR 
 
PRIMARY 
ENDPOINTS 
STUDY 
PARTICIPANTS 
TREATMENT GROUPS RESULTS  
Meier et al. 78 
 
 
Lumbar and 
femoral neck 
BMD, bone 
turnover 
markers, 
calciotropic 
hormones 
55 male and female 
healthy subjects aged 
33-78 years, 
(Germany). 
Intervention: 12.5ug D3 + 
500mg Ca (n=30)  
Control: no placebo 
Increases to Lumbar and 
femoral neck BMD over 
1 year (+0.8%, p=0.04 
and 0.1%, p=0.05, 
respectively) in 
intervention group 
compared to control. 
 
Porthouse et al. 66 
 
 
Clinical 
Fractures 
3314 women aged 70+ 
with one or more 
factors for hip fracture. 
(UK) 
Intervention: 20ug D3+ 
1,000mg Ca 
(n=1321)  
Control: leaflet only 
OR= 1.01 (95% CI 
=0.71-1.43) in 
Supplement group, non-
significant. 
 
Moschonis & 
Manious 73 
 
 
BMD 101 post menopausal 
women aged 55-65 
(Greece) 
Dietary Group: 7.5ug D3+ 
1200mg Ca, through 
fortified dairy (n=39) vs 
Supplement Group: 600mg 
Ca vs Control: no placebo 
Dietary group total body 
BMD using DXA 
significantly increased 
(<0.001) over other 
groups. No significant 
BMD changes in 
supplement group 
compared to control. 
 
Law et al.77 
 
 
 
Fractures and 
falls 
3,717 elderly 
residential care men 
and women, mean age 
85 years (UK) 
Intervention: 2,500ug D2 
every 3 mths  
Control: no placebo 
Reported at least one 
fall: 44% in Vitamin D 
vs 43% in control, no 
statistical differences in 
fracture between groups. 
 
Meyer et al.74 Fractures 1,144 Nursing home 
residents, men and 
women,  mean age 85 
(Norway) 
Intervention: 5ml cod liver 
oil (n=569)  
Control: 5ml placebo cod 
liver oil with vitamin D 
(n=575) removed 
No difference in hip 
fracture (p=0.66, log 
rank test) or nonvetebral 
fracture (p=0.60, log 
rank test) in vitamin D 
group compared to 
control group. 
 
Lyons et al. 75 Fractures 3,440 Nursing and 
residential care men 
and women, mean age 
84 (UK) 
Intervention: 2,500ug D2 
every 4mths (n=1,725) 
Control: Placebo 
HR 0.95 (95% CI 0.79-
1.15) for intervention 
compared to control was 
not statistically 
significant. 
 
Trivedi et al. 72 Fracture 
Incidence and 
Total Mortality 
2,686 men and women 
from the general 
community, aged 65-
85 
(UK) 
Intervention: 2,500ug D3 
every 4mths (n=1345) 
Control: placebo 
RR in Vitamin D group 
compared to Control 
was 0.78 (95% CI 0.91-
0.99; p=0.04) for first 
time fracture and 0.69 
(95% CI 0.48-0.93; 
p=0.02) for wrist, 
vertebral or hip fracture. 
 
Larsen et al. 70 Low energy 
fractures 
9,605 community 
dwelling men and 
women aged 66+ years 
(Denmark) 
Intervention: 10ug D3 + 
1,000mg Ca 
Control: domestic hazard 
reduction  
RR in Vitamin D and Ca 
was 0.84 (95% CI 072-
0.98; p<0.025). 
Significant reduction in 
osteoporotic fracture in 
intervention group. 
 
Grant et al. 67 New low 
trauma hip 
fracture 
 
5,292 men and women 
aged &70 + (UK) 
Interventions: 20ug D3 or 
1,000mg Ca or combination 
20ug D3 and 1,000mg Ca  
Control: placebo 
Between combination 
intervention and placebo 
(HR=1.01 95% CI 0.75-
1.36;), no significant 
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effects on fracture 
incidence   
from any interventions. 
 
Jackson et al. 71 Hip Fracture 
and Hip BMD 
 
36,282 women aged 
50-79. (US) 
Intervention: 10ug D3 + 
1,000mg Ca 
Control: Placebo 
For Hip fracture = 
(HR=0.88  95% CI 0.72-
1.08; p=0.14), 
significant  6% increase 
in hip density 
(p=<0.001). 
 
Harwood et al. 76 
 
 
BMD and falls 150 women following 
surgery for hip fracture 
with mean age of 
81.(UK)  
Interventions: single 
7,500ug injection D2 with 
or without 1,000 Oral Ca or 
20ug D3 + 1,000mg Ca. 
Control: no placebo 
Average 4.6% increase 
in BMD between 
Intervention groups 
compared to Control 
group 
 
Vitamin D and Muscle Strength 
 
There has been much recent interest and research with regard to the role vitamin D 
plays in muscle strength and function. This is a very important area as poor muscle 
strength and function negatively impact upon balance and body sway, which in turn 
increase risk of falling86,87. Falls are a serious health concern as they are a major cause 
of fractures and morbidity in older adults, with data from the Australian Institute of 
Health and Welfare showing that falls resulted in an estimated 60,497 hospitalizations 
in 2003-04 for people over 65 years of age in Australia88.  
 
One of the main pathways by which vitamin D is thought to effect muscle function is 
through the binding of 1,25 dihydroxyvitamin D to nuclear receptors on skeletal 
muscle, this stimulates, via gene transcription, protein synthesis which in turn impacts 
on muscle growth86,88,89. Thus, vitamin D’s role in reducing fracture risk may be 
explained not only by its role in maintaining BMD and making it less likely bones 
will fracture when a fall occurs, but also by actually reducing the risk of a fall in the 
first place via 1,25(OH)2D’s role in maintaining muscle strength and balance. This 
role of 1,25(OH)2D on skeletal muscle strength has been supported by a number of 
studies that have directly tested the muscle strength of participants, as well as fall and 
balance studies which have shown significant relationship between lower serum 
25(OH)D status and poorer muscle strength and increased fall risk.  
 
Vitamin D and studies directly measuring muscle strength 
 
Two large examples that have directly tested the muscle strength of participants, are 
the Osteoporosis Prospective Risk Assessment study (OPRA) and the recent InChianti 
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study82,90. Both of these studies showed statistically significant associations with 
serum 25(OH)D and handgrip strength at the multivariate level (men p=0.04 and 
women p=0.01) and correlations of 25(OH)D with thigh muscle strength (Spearman’s 
rank test r=0.08, p=0.02) for the InChianti and OPRA studies respectively82,90. 
 
These studies had large samples of randomly selected participants, the OPRA study 
using a sample of 986 of elderly women and the InChianti study using 976 males and 
females participants over 65 years and as such have provided strong evidence for the 
role of serum 25(OH)D in muscle strength82,90.  Similarly, in a large US based survey 
(n=4100) of people over 60, Bischoff-Ferrari et al.91 found that levels of serum 
25(OH)D under 40nmol/L were associated with decreased muscular function in the 
lower extremities. Other cross-sectional and cohort studies have also shown this 
trend92-94, however, one of these92 only showed a correlation between 25(OH)D and 
muscle strength in males while the active 1,25(OH)2D form was correlated with 
muscle strength in both females and males.  
 
However not all studies have shown a relationship between muscle strength and 
serum 25(OH)D. Verreault et al.95 conducted a prospective cohort study with a 3-year 
follow up in older, disabled women (n=628) which showed no relationship in muscle 
strength, walking speed or repeated chair stands for groups stratified by serum 
25(OH)D status (>53nmol/L ,25-52nmol/L, <25nmol/L). Despite a high quality 
observation design, however, this study only measured moderately to severely 
disabled older women whose physical function was more then likely below baseline, 
so its applicability to ambulatory or even non-disabled elderly is severely limited. One 
of the major limitations of all of the above observational studies is, of course, their 
inability to infer a causal relationship between muscle strength and serum 25(OH)D 
due to their non-experimental design. Two recent Randomised Controlled Trials, 
however, have found no relationship between muscle strength measures and vitamin 
D 96,97. Kenny et al.97, provided 1,000IU (25ug) vitamin D3 supplementation over 6 
months to a group of ambulatory older men (65+) and provided a placebo to the 
control (total n=65). Handgrip strength, leg extension and a short physical 
performance battery was used to test muscle strength at baseline and following six 
months and while there was a significant increase in 25(OH)D status in the 
intervention group, no significant changes were seen in physical performance or 
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muscle strength. Latham et al.96 used a larger sample of older frail elderly (n=243) 
and supplemented the intervention group with a single 300,000IU (7,500ug) dose of 
calciferol at the beginning of the trial. Physical performance indicators of leg 
extension, Berg balance test, timed up and go test and time to walk a 4 meters 
distance were tested at baseline, 3 months and 6 months96. At six months, calciferol 
supplementation had no significant impact on functional performance in these 
participants. Both these studies where well designed RCT’s and together seem to 
indicate vitamin D supplementation had no effect on either healthy ambulatory men 
or the older frail elderly.  However the results need to be interpreted with caution as 
relatively small numbers where used in both studies and only a small subgroup within 
the samples were classified as serum 25(OH)D deficient, while in comparison, the 
larger InChianti observational study had a much larger number of serum 25(OH)D 
deficient participants available for analysis. It is therefore likely that only vitamin D 
deficient groups may benefit from supplementation. 
 
In the future areas of research may include a greater emphasis for the role of raised 
parathyroid hormone levels, which have been linked independently with lower muscle 
strength, resulting in both low vitamin D and the related secondary 
hyperparathyroidism causing a loss of functional ability and balance98. The 
measurement of 1,25(OH)2D levels and its association with muscle strength may also 
be an area of some promise, as the study by Bischoff-Ferrari et al.92 showed this was 
correlated with muscle strength in both males and females. 
Recent research has also focused on the role of VDR polymorphisms on muscle 
strength and fall risk89,90. Winderlinkx et al.99 used genotyping in 493 men and 
women to show that various polymorphisms where associated with quadriceps 
strength in both men and women.  
 
Vitamin D and Fall Risk 
 
The main health outcome of reduced muscle strength and function is an increase in 
fall risk due to decreased balance and increased body sway. As a result of this, studies 
investigating the relationship between serum 25(OH)D and falls are more numerous 
than those that have directly investigated muscle strength and many of these studies 
have shown significant relationships between vitamin D supplementation or serum 
25(OH)D status and reduced fall risk100-105. In a meta-analysis of 5 RCT’s, Bischoff-
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Ferrari et al.106 reported that vitamin D supplementation with vitamin D3, calcitriol or 
calcidiol reduced the risks of falling by 22% (corrected OR= 0.78, 0.64-0.92). 
Another meta-analysis by Jackson et al.107, which analyzed 5 studies (4 RCT’s and 
one prospective observational study), reported a pooled relative risk of 0.88 (CI, 0.78-
1.00) for Vitamin D3 reducing falls. These meta-analyses included total sample sizes 
of 1,237 and 1,885 (both institutionalized and ambulatory) adults respectively and 
provide strong evidence for the role of vitamin D reducing in the risk of falls in both 
institutionalized and ambulatory adult populations.  
 
A number of studies have not found a relationship between fall risk and serum 
25(OH)D levels or vitamin D supplementation. RCT’s conducted by Dawson Hughes 
et al.108 and Chapuy et al.109 both showed no significant effect on falls for vitamin D3 
supplementation of 700IU and 800IU over three and two years, respectively. This was 
despite significant increases in serum 25(OH)D status in both studies.  Thus, despite 
some strong evidence showing a reduction in falls risk for people with higher serum 
25(OH)D status, there remains numerous inconsistencies in the evidence base. Large, 
well designed RCT’s are really needed to overcome these inconsistencies as many of 
the studies have relied on small numbers of participants, which affects the 
generalisibility of the results.   
 
Summary 
 
Vitamin D’s role in muscle strength and fall risk is a relatively new area and thus 
many gaps exist in our knowledge. For instance, many of these trials also used 
supplemental calcium due to the proposed effect of both calcium and vitamin D on 
falls, but few used vitamin D and calcium supplementation and compared it to 
vitamin D alone. Dukas et al.100 however showed that only those with a calcium 
intake above 512mg/d had a significant reduction in fall risk with alfacalcidiol 
supplementation, suggesting this may be an important area of research.  A number of 
studies also compared calcium vs calcium and vitamin D showing vitamin D2 or 
vitamin D3 and calcium to be significantly more effective in reducing falls then 
calcium alone98,104.  Also few studies with regard to muscle strength and fall risk have 
been conducted in an Australian setting, which is disappointing when considering the 
enormous health burden that falls and osteoporosis place on this country.  
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Vitamin D and Cancer 
 
Vitamin D’s possible role in the prevention of some types of cancer is one of the most 
important areas of research involving vitamin D, due to enormous health impact of 
cancer worldwide. Research suggesting vitamin D had a role in cancer can be traced 
back to an ecological study by Apperly110 which initially linked ultraviolet radiation 
exposure with cancer incidence in the US. Although the link between vitamin-D, UV 
exposure and cancer was not directly made, this landmark study showed that people 
in northern US states with low UV exposure such as New Hampshire where more 
likely to die of cancer then those living in southern states such as Texas with high UV 
exposure111. It was only through later studies, however, that Vitamin D was linked as 
a possible factor in reducing cancer risk112.  
 
A variety of possible anti-carcinogenic biological mechanisms have been proposed to 
explain Vitamin D’s role in reducing cancer risk. 1,25(OH)2D (the active Vitamin D 
form) is involved, via its nuclear Vitamin-D Receptor (VDR), in the regulation of cell 
differentiation, cell growth, apoptosis (cell death) and various cellular mechanisms 
that play a role in cancer development54. For instance, 1,25(OH)2D  has been shown 
to be active in cell cycle control via p21, p23 and p53 proteins, which block DNA 
damaged cells progressing in the cell development cycle54. Also, it has been proposed 
that 1,25(OH)2D has a role in inducing apoptosis and inhibiting angiogenesis once a 
cell becomes malignant, therefore reducing the ability of the malignant cell to 
survive48. Importantly colon, prostate and mammary cells have demonstrated the 
ability to extrarenally synthesize 1,25(OH)2D, which may play a role in modulating 
cell proliferation and apoptosis at the local level113. 
 
The variety biological mechanisms, in which 1,25(OH)2D can affect cancer 
development, shown by experimental in-vitro studies, provide a good biological basis 
for the protective role of vitamin D in cancer. However, there is obviously a need for 
well designed, population-based epidemiological studies to provide evidence of this 
association. The main types of cancer vitamin D have been linked to are: colorectal, 
breast and prostate, however links with other types of cancer such as lung, ovarian 
and endometrial have also been suggested112.  
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Prostate Cancer 
 
Studies investigating the relationship between vitamin D and prostate cancer have 
produced contradictory evidence114. Hanchette and Schwarz115 showed a highly 
significant (p=<0.0001) inverse relationship between UV exposure and prostate 
cancer risk in a large US ecological study and hypothesized that the high prostate 
cancer risk in those areas with lower UV exposure was due to their lower vitamin D 
levels. Even at the time of this study (1992), the possible anti-tumor effects of vitamin 
D were well known and the presence of VDR’s on prostate cells indicated a role for 
vitamin D in the regulation of prostate cell growth116. However ecological studies 
have many weaknesses including a very high risk of confounding, so further research 
using higher quality research designs was warranted to test this hypothesis. 
 
 A number of recent case-control designs have found associations between serum 
25(OH)D and prostate cancer117-119. Ahonen et al117, showed that men aged under 52 
with serum 25-hydoxyvitamin D levels below 40nmol/L were three and a half times 
more likely to be diagnosed with prostate cancer (OR=3.5, 1.7-7.0; p<0.0006) while 
men over 52, with the same low levels of serum 25(OH)D had almost no increase in 
risk (OR=1.2, 0.7-2.1; p not reported). One possible reason proposed by the authors 
for this is that vitamin D may inhibit androgen-induced prostate cell proliferation and 
men over 50 have increasingly lower androgen activity, therefore vitamin D has a 
much reduced effect on prostate cancer risk in older men117. A second larger case-
control study interestingly showed a U-shaped association whereby groups of 
participants who where <19nmol/L and >80nmol/L showed an increased risk of 
prostate cancer (OR 1.5, CI 0.8-2.7 and OR 1.7, CI 1.1-2.4), respectively114. The 
authors hypothesized that the group with higher serum 25(OH)D may have 
experienced a higher risk of prostate cancer due to higher intakes of vitamin A or by 
increased activation of 24-hydroxylase (an enzyme which inactivates Vitamin D), 
leading to local vitamin D deficiency in the prostate gland114. Studies by Gann et al.118 
and Platz et al.119, however have shown no relationship between either 1,25-
dihydroxyvitamin D or 25-hydroxyvitamin D and prostate cancer, although both of 
these studies did not rule out small to moderate effects or effects at later disease 
stages, respectively.  
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All of these studies suffer limitations due to their case-control design, so we cannot 
infer any causal relationship. Also geographical differences (Scandinavian studies 
tended to have lower mean and median serum 25(OH)D), season of blood draws, 
control matching and follow up time all make it difficult to form a consistent picture. 
Further research using higher quality research designs such as large cohort studies are 
needed to better determine the relationship between vitamin D and prostate cancer. 
 
 
Breast Cancer  
 
Vitamin D’s role in breast cancer etiology has been one of the major areas of vitamin 
D and cancer research. This has been due, in part at least, to ecological studies 
showing geographical differences in breast cancer mortality or incidence that were 
closely associated with differences in UV exposure118. Experimental evidence has 
provided some strong support for the hypothesis that vitamin D may have a protective 
role against breast cancer. In-vitro studies have shown that 1,25(OH)2D can stimulate 
apoptosis, cell cycle arrest and reduce estrogen receptor expression in MCF-7 breast 
cells121.  
 
 
Two epidemiological studies by Lowe et al.122 and Bertone-Johnson et al.123 have 
investigated circulatory 25(OH)D levels and breast cancer risk. Lowe et al.120 
recruited hospital breast cancer patients (n=179) and controls (n=170) and reported 
that women with 25(OH)D levels <50nmol/L had an OR of 3.54 (95% CI 1.89-6.61; 
p<0.001) compared to those women with 25(OH)D levels >50nmol/L. In a larger 
study by Bertone-Johnson et al.123 (cases, n=701; controls, n= 724) women with the 
highest quintile of 25(OH)D had a 27% decreased risk of breast cancer compared to 
those in the lowest quintile (RR=0.73, 95% CI 0.49-1.07; p trend=0.06). 1,25(OH)2D 
was also tested in this study but non-significant results were found. Both of these 
studies provide evidence for an inverse association of higher serum 25(OH)D with 
breast cancer risk, although a weakness of both of these studies was that serum 
25(OH)D was tested only once and not repeated, which may not reflect long term 
serum 25(OH)D status. It could also be argued that serum 25(OH)D status may not 
accurately reflect the local concentration of the active form of vitamin D, 
1,25(OH)2D, which has been shown in vitro to mediate anti cancer effects in breast 
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cells (see above). Lowe et al.122, comments on this by postulating that adequate serum 
25(OH)D is needed to provide a substrate for the 1-alpha hydroxylase enzyme in 
breast cells that produce the active 1,25(OH)2D locally.  
 
A number of studies have also explored the relationship between vitamin D intake, 
sun exposure and risk of breast cancer. Cohort studies undertaken by Shin et al.124, 
McCollough et al.125, John et al.126 and Robien et al.127 all found some inverse 
associations between vitamin D intake and or exposure and breast cancer risk. Shin et 
al.124, as part of the Nurses Health Study (n=88,691) reported no significant 
associations between total (dietary and supplemental) vitamin D intake and breast 
cancer incidence in postmenopusal women but did report significant associations 
when comparing the lowest total vitamin D intake (<3.75ug) to the highest vitamin D 
intake (>12.5ug) in premenopausal women (RR=0.72 95% CI 0.55-0.94; p= .01). 
McCollough et al.125 conducted another study into a large cohort (n=68,567) as part of 
the Cancer Prevention Study II Nutrition Cohort and showed a statistically significant 
relationship between estrogen receptor positive tumors and dietary vitamin D intake 
(RR=0.74 95% CI: 0.57-0.93; p=0.006), but overall breast cancer risk was not 
associated with vitamin D intake. Robien et al.127 reported a weaker non-statistically 
significant relationship with a relative risk of 0.89 (95% CI: 0.77-1.03; p=0.12) for 
women with a vitamin D intake of >20ug in the Iowa Women’s Health Study 
(IWHS). All of these studies are notable due to their large size and prospective cohort 
design, however as these were observational studies a causal relationship cannot be 
confirmed and both studies did not adequately measure sun exposure, which is the 
main source of vitamin D for most populations. John et al.126 in the NHANES I study 
(n=5009), however did measure sun exposure via interview as well as dietary and 
supplemental intake of vitamin D. While this study did not show overall vitamin D 
was associated with breast cancer reduction it did infer that vitamin D intake 
(>5ug/day) and high solar radiation was associated with a reduction in risk (RR=0.71 
95% CI 0.44-1.14), however this was not statistically significant126. Two major 
limitations of this study were the relatively small number of breast cancer cases 
detected which limited statistical power and the use of 24 hr dietary recall methods 
which rarely represent participants usual dietary intake. 
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A recent high quality, double-blind, placebo controlled randomised controlled trial 
conducted by Lappe et al.128 has provided a boost to evidence of vitamin D’s role in 
breast cancer reduction. While the primary outcome of this study was fracture 
incidence, a secondary outcome was cancer incidence. This study was conducted over 
a four year period with a randomly selected population of 1179 community-dwelling 
women aged >55128. A significant relationship between lower breast cancer risk in the 
calcium and vitamin D3 supplementation group (1,400-1,500mg/d and 27.5ug/d, 
respectively) compared to the placebo group (RR=0.402, CI: 0.20-0.82;P=0.013) was 
reported, furthermore, calcium plus cholecalciferol proved more effective at reducing 
risk of breast cancer then calcium alone128.  
 
There has also been much recent interest in the role VDR polymorphisms such as 
Bsm1, Apa1, Taq1 and Poly(A) and breast cancer risk, however studies into these 
have produced highly inconsistent results, probably related to methodological issues 
such as small sample sizes121. So, despite some promising experimental and 
epidemiological results, vitamin D’s role in breast cancer prevention is still an area of 
some debate and further well designed intervention studies such as that undertaken by 
Lappe et al.128, and observational studies that use validated tools to collect sun 
exposure and dietary vitamin D data are needed to strengthen the evidence base. 
 
Colorectal Cancer 
 
As was the case for prostate and breast cancer, colorectal cancer and the possible 
protective role of vitamin D was first proposed in a landmark ecological study 
conducted by Garland and Garland129 showing an inverse relationship between UV 
exposure and colorectal cancer risk. Since then, experimental data has shown that 
1,25 (OH)2D may be involved in controlling cell growth and differentiation in colon 
cells and the ability of the colon to convert 25(OH)D to active 1,25(OH)2D via local 
1-alpha-hydroxylase activity113. 
 
A meta-analysis of studies that have assessed the association between serum 
25(OH)D status and colorectal cancer was conducted by Gorham et al.130. This 
analysis identified 5 nested case-control studies (total n=1,448) using pre-diagnostic 
serum from healthy volunteers who were followed up between 2 to 25 years for 
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incidence of colorectal cancer.  Results from the pooled analysis of this study showed 
serum 25(OH)D levels >83 nmol/L were associated with a 50% lower risk of 
colorectal cancer compared to serum 25(OH)D levels <30nmol/L130. A number of 
studies have also shown a relationship between dietary vitamin D intake and 
colorectal cancer risk, including a systematic review by Gorham et al.131, which 
included analysis of 14 epidemiological studies investigating vitamin D intake and 
colorectal cancer. The authors summarized that vitamin D intakes of >25ug/d were 
associated with a decrease in colon cancer risk of approximately 50% compared to 
vitamin D intakes of <2.5ug/d131. It should be noted, however, that groups with 
high/moderate sun exposure and displaying adequate to optimal serum 25(OH)D 
levels, even with low vitamin D dietary intakes would almost certainly not obtain the 
same benefits as described above. This is supported by the fact that many of the 
studies supporting the role of oral vitamin D intake and colon cancer prevention are 
conducted in high latitude northern countries displaying low baseline serum 25(OH)D 
levels and are therefore most likely to benefit to increased oral vitamin D intake130.   
Other studies have shown a null relationship, for instance the recent, large Women’s 
Health Initiative (n=36,282) RCT reported no statistically significant difference in 
colorectal cancer risk in women receiving both calcium (1,000mg/d) and vitamin D3 
(10ug/d) supplements compared to those receiving a placebo over a seven year follow 
up132. One significant weakness of this study was its use of relatively low doses of 
vitamin D3, when other studies have found doses of 25ug/d may be needed to 
significantly reduce risk of colon cancer131. Although causal inference cannot be 
inferred due to observational study designs, there is a growing body of evidence 
showing vitamin D may reduce the risk of colorectal cancer. However, the data is not 
fully consistent with some large, well-designed studies such as that conducted by 
Wactawski et al.132 showing no association. A large well designed RCT with similar 
methodology to the Women’s Health Initiative, but using higher vitamin D doses (eg. 
25ug/d) and a longer follow up is needed to establish a causal link between vitamin D 
and colorectal cancer risk. 
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Summary of vitamin D’s role in cancer 
 
Despite the strong experimental in vitro and ecological data that supports a possible 
role for vitamin D in reducing cancer risk, epidemiological evidence is relatively 
inconsistent, at least for most types of cancer. The use of latitude gradients of disease 
based on erythemal UV levels, which has formed the basis of many of the ecological 
studies, has been recently called into to serious question with actual vitamin D 
producing UV showing significant differences to erythemal UV based on latitudes21. 
Ecological based studies using geographical variations in UV exposure are also 
subject to a high degree of error due to major variations in individuals UV exposure 
for each given area, so these studies need to be interpreted with caution. Also most of 
the studies showing a link between vitamin D and cancer, are observational so causal 
linkage cannot be inferred. There is also the alternative explanation, in light of the 
inconsistencies, that serum 25(OH)D status may not be linked to cancer. 
Observational designs are at high risk of confounding, so confounding factors such as 
obesity which is linked both to increased cancer risk and low serum 25(OH)D status 
may possibly explain some of the positive findings133. 
There does however appear to be a growing body of in vitro and observational 
evidence supporting a role for vitamin D, especially in breast and colorectal cancers 
and large intervention trials are really needed to confirm causal linkages. Also, while 
much of the focus has been on vitamin D and breast, prostate and colorectal cancers, 
further research into the possible roles of vitamin D and other cancers such as lung 
and endometrial is needed. 
  
 
Other proposed roles of vitamin D in disease prevention 
 
Due to the widespread distribution and identification of VDR’s in many human tissue 
types, interest in vitamin D’s role in the etiology of other disease classes such as 
autoimmune and cardiovascular diseases has been of great interest to researchers. 
Other roles for vitamin D in disease etiology continue to be found, for instance, a 
recent example of an antimicrobial role for vitamin D was demonstrated with the 
finding of a vitamin D receptor mediated innate immune response against 
mycobacterium tuberculosis, resulting in bacterial killing134. 
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Vitamin D and autoimmune Diseases 
 
VDR’s have been identified in dendritic cells, antigen presenting cells, mononuclear 
cells and activated T and B lymphocytes135. Additionally, 1-alpha hydroxylase 
activity is expressed by activated macrophages and dendritic immune cells136. A 
number of possible mechanisms for the role 1,25(OH)2D in immune regulation have 
been identified, these include the down regulation of Th1 cell activity, decreased 
release of cytokines from macrophages and B cell antibody production and reduced 
release of IL-2 and IFN-y by CD4 T cells137.A number of recent epidemiological 
studies have found associations between serum 25(OH)D status138,139 or total intake of 
dietary vitamin D via dietary and supplemental sources140,141 and common 
autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, inflammatory 
bowel diseases, systemic lupus erythematosis and type-1 diabetes mellitis142. Of 
particular note, due to its large prospective cohort design is the study conducted by 
Munger et al.140 as part of the Nurses Health Study I and II (92,253 women between 
1980-2000 and 95,310 women between 1991-2001, respectively) in which dietary 
vitamin D intake was assessed against risk of multiple sclerosis in the two cohorts. 
Pooled analysis comparing women in the highest quintile of vitamin D intake to those 
of the lowest quintile revealed an age adjusted Relative Risk of 0.67 (95% CI: 0.40-
1.12; p=0.03), suggesting a strong inverse association between total intake of vitamin 
D and multiple sclerosis142. Other studies have suggested relationships between serum 
25(OH)D status and development of autoimmune disease138,139. While these results, 
combined with experimental models are promising, a significant amount of our data is 
still sourced from ecological studies. More data using intervention trials is really 
needed to confirm whether higher serum 25(OH)D status is actually protective against 
certain autoimmune diseases, or that these positive associations are the result of 
confounding factors. 
 
 
Vitamin D and Cardiovascular Diseases 
 
Vitamin D’s role in the etiology of cardiovascular disease is an area of great debate as 
epidemiological studies have reported inconsistent results. Ecological studies such as 
that conducted by Zitterman et al.143 have shown higher cardiovascular disease (CVD) 
rates in higher latitudes and in winter months where sunlight exposure is less. This 
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lead to the hypothesis that vitamin D, the main beneficial outcome from sunlight 
exposure, is linked to CVD etiology. As in cancer studies, ecological studies based on 
UV exposure by latitude or season are very limited as large individual variations are 
commonplace. As a result of this, no firm causal links have been established as yet; 
however vitamin D has also been linked inversely to risk factors for CVD events such 
as hypertension (via inhibition of the Renin Angiotensin and Aldosterone System 
(RAAS)), diabetes and inflammation144. 
The recent Women’s Health Initiative Randomized Trial, however, reported no 
association between women taking 5ug/d of vitamin D twice a day and CVD risk over 
a 7-year follow up145.  However, as discussed if other sections of this paper, 10ug 
(400IU) of vitamin D per day may not provide an adequate dose to produce a 
preventative effect on disease. Research into vitamin D’s role in CVD is still a 
relatively new area and new large RCT’s with adequate doses of vitamin D and 
follow up are really needed to confirm a causal relationship, however with the 
enormous burden of disease that CVD places on the population, this is an extremely 
important area of ongoing and future vitamin D research. 
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CONCLUSION 
 
Vitamin D is unique among the micronutrients in that while it is described as a fat-
soluble vitamin it is more accurately classified as a steroid hormone. This is due to its 
action via specific vitamin D receptors and the fact that most of our requirements are 
sourced from non-dietary means via UV radiation from sunlight exposure. As a result 
of the wide distribution of vitamin D receptors in human tissues, vitamin D’s role in 
human health is also diverse ranging from its widely known function in bone health to 
possible roles in the prevention of certain cancers. 
 
When it is considered that most humans rely on UV radiation, a known carcinogen, to 
synthesize the vast majority of their vitamin D, this creates a major worldwide health 
dilemma. This dilemma is further enhanced when it is considered that vitamin D 
deficiency has been identified as a problem in a sunny country such as Australia, 
which known as the skin cancer capital of the world. In countries, which have lower 
sunlight exposure such as in Northern Europe, inadequate vitamin D is an even 
greater problem. Wider spread fortification, as seen in some countries, or 
supplementation may be the most practical measures to alleviate suboptimal vitamin 
D levels, at least in vulnerable populations. 
 
Vitamin D deficiency and indeed suboptimal vitamin D status plays a major and 
increasingly broad and complex role in health and disease. While vitamin D’s 
functions in bone health are widely known, its importance is set to grow in this area, 
driven by aging populations in western societies which are contributing to ever 
growing numbers of people suffering osteoporosis. Furthermore, with the discovery 
of the widespread distribution of vitamin D receptors and enzyme activity in various 
human tissues, biologically plausible mechanisms have appeared to support previous 
epidemiological evidence suggesting links with various diseases and conditions 
beyond bone health. These include roles in cancer, autoimmune disease, 
cardiovascular disease and muscle function. Whilst there have been many promising 
findings for these ‘new’ areas of vitamin D research, much remains to be discovered 
and in some cases the epidemiological evidence as a whole has been inconclusive. 
Many of the designs used are observational and are therefore at high risk of 
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confounding. This raises the possibility that some positive associations seen between 
serum 25(OH)D and disease may be influenced by confounding factors such as 
obesity and lifestyle.  In conclusion, future research with an emphasis on high quality 
observational and experimental designs is needed to further elucidate the role and 
potential public health impacts that vitamin D may offer for both traditionally 
associated roles such as bone health and more recent potential benefits for diseases 
such as cancer and cardiovascular disease. 
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